Alagebrium chloride: Phase IIb

ALT began the U.S. Phase IIb SPECTRA trial in about 390 patients with a systolic blood pressure of at least 140 mm Hg. Following a wash-out period, patients will receive 1 of 3 daily doses of alagebri...